Chemomab Therapeutics Ltd.
Stock Forecast, Prediction & Price Target
Chemomab Therapeutics Ltd. Financial Estimates
Chemomab Therapeutics Ltd. Revenue Estimates
Chemomab Therapeutics Ltd. EBITDA Estimates
Chemomab Therapeutics Ltd. Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $24.4M Low: $24.4M High: $24.4M avg. 0% | Avg: $36.2M Low: $36.2M High: $36.2M avg. 48.36% | Avg: $0 Low: $0 High: $0 avg. -100% |
Net Income
% change YoY
| $-12.55M N/A | $-27.64M -120.19% | $-24.22M 12.38% | Avg: $-23.14M Low: $-11.98M High: $-469.99K avg. 4.45% | Avg: $-27.20M Low: $-11.04M High: $-587.49K avg. -17.55% | Avg: $-4.19M Low: $-4.19M High: $-4.19M avg. 84.59% | Avg: $-4.50M Low: $-4.50M High: $-4.50M avg. -7.47% |
EBITDA
% change YoY
| $-12.36M N/A | $-28.47M -130.24% | $-25.39M 10.82% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$1.21 N/A | -$2.43 -100.82% | -$2.06 15.22% | Avg: -$0.37 Low: -$1.02 High: -$0.04 avg. 82.03% | Avg: -$0.35 Low: -$0.94 High: -$0.05 avg. 6.30% | Avg: -$0.36 Low: -$0.36 High: -$0.36 avg. -2.88% | Avg: -$0.38 Low: -$0.38 High: -$0.38 avg. -7.47% |
Operating Expenses
% change YoY
| $12.36M N/A | $28.53M 130.71% | $25.45M -10.77% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Chemomab Therapeutics Ltd. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 16.00% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -11.98M, average is -23.14M and high is -469.99K.
What is Chemomab Therapeutics Ltd. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 12.09% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Chemomab Therapeutics Ltd. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.49% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.02, average is -$0.37 and high is $-0.04.